Doctors injected one tumor and watched cancer vanish from the entire body, offering real hope against deadly diseases without Big Pharma’s toxic side effects.
Story Highlights
- Rockefeller University’s 2141-V11 immunotherapy shrank tumors in 6 of 12 phase 1 patients, with 2 achieving complete remission in aggressive melanoma and breast cancer.
- Direct injection into one tumor eliminated distant tumors body-wide, bypassing intravenous toxicity that plagued prior therapies.
- Expanded trials now underway with nearly 200 patients targeting tough cancers like prostate, bladder, and glioblastoma.
- Cancer survival rates hit 70% thanks to advances in immunotherapy, validating decades of research into the body’s natural defenses.
Phase 1 Trial Delivers Remarkable Results
Researchers at Rockefeller University tested 2141-V11, a redesigned CD40 agonist antibody, in 12 patients with metastatic cancers. Direct intratumoral injection triggered immune responses that shrank tumors in six participants.
Two patients—one with melanoma, one with metastatic breast cancer—saw all detectable cancer disappear. This outcome occurred despite injecting only one tumor, as distant lesions also vanished.
No severe side effects appeared, unlike past intravenous CD40 drugs that caused widespread toxicity due to CD40 receptors on healthy cells.
Breakthroughs like this are why sustained investment in biomedical science matters.
In an early trial, injecting immunotherapy into one tumor triggered immune responses across the body – with 50% of patients responding and some complete remissions.
Science saves lives. pic.twitter.com/V26f705tou
— Dr. Catharine Young (@DrCatharineY) March 18, 2026
Innovative Delivery Method Unlocks Systemic Power
The Leonard Wagner Laboratory team engineered a more potent CD40 antibody and shifted to a local injection strategy. This activated dendritic cells, T cells, and B cells within tumors, forming lymph node-like structures that orchestrated body-wide attacks on cancer.
Jeffrey Ravetch noted a melanoma patient with dozens of leg tumors had only one thigh lesion injected—yet all others disappeared after repeated doses.
Juan Osorio called the shrinkages and remissions remarkable in such a small group. This approach harnesses the immune system precisely, minimizing harm to patients.
Historical Setbacks Overcome by Smart Science
CD40 agonists disappointed for decades because intravenous delivery hit healthy tissues hard, limiting doses. Rockefeller’s innovation confines activation to the tumor site, sparking localized firepower that spreads systemically. Tumors filled with immune aggregates resembling tertiary lymphoid structures are linked to better outcomes.
This builds on immunotherapy gains, such as melanoma survival rising from 16% to 35% with checkpoint inhibitors. Common-sense engineering turned a flawed idea into a promising weapon against cancer’s spread.
Expanded Trials Target Hard-to-Treat Cancers
Phase 1 results published in Cancer Cell propel 2141-V11 forward. Expanded phase 1 and 2 studies now enroll nearly 200 patients with bladder, prostate, and glioblastoma—cancers frustrating traditional treatments.
Collaborations with Memorial Sloan Kettering and Duke University broaden testing. Researchers seek biomarkers such as high T cell clonality to predict responders, enabling personalized treatment.
While not all phase 1 patients responded, larger trials dissect why, promising tailored therapies that respect individual biology.
New Cancer Immunotherapy Killed Whole Tumors
Researchers at Rockefeller University are reporting encouraging results from an early clinical trial of a redesigned cancer immunotherapy that is injected directly into tumors.
In the small study, six of 12 patients experienced…
— NENE'S MOMMA (@DebrulerTerri) March 18, 2026
Placing Breakthrough in Broader Immunotherapy Surge
This advance joins 2026’s wave, including UCLA’s CAR-NKT cells for pancreatic cancer and KAIST’s CAR-macrophages via intratumoral injection. All emphasize immune activation over poisons, affecting non-injected tumors with less toxicity. Five-year cancer survival now reaches 70%, driven by such innovations.
Under President Trump’s America-first push for efficient science, these developments cut waste from overregulated, globalist drug pipelines. Patients gain real options, affirming faith in American ingenuity and self-reliance over endless government spending.
Sources:
ScienceDaily (Rockefeller University)
